217 related articles for article (PubMed ID: 30578743)
21. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
Cloos J; Goemans BF; Hess CJ; van Oostveen JW; Waisfisz Q; Corthals S; de Lange D; Boeckx N; Hählen K; Reinhardt D; Creutzig U; Schuurhuis GJ; Zwaan ChM; Kaspers GJ
Leukemia; 2006 Jul; 20(7):1217-20. PubMed ID: 16642044
[TBL] [Abstract][Full Text] [Related]
22. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
Luskin MR; DeAngelo DJ
Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
24. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
25. Potential targeting of FLT3 acute myeloid leukemia.
Ambinder AJ; Levis M
Haematologica; 2021 Mar; 106(3):671-681. PubMed ID: 32703795
[TBL] [Abstract][Full Text] [Related]
26. Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.
Muffly L; Young C; Feng Q; Nimke D; Pandya BJ
Leuk Lymphoma; 2023; 64(11):1832-1839. PubMed ID: 37486091
[TBL] [Abstract][Full Text] [Related]
27. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
[TBL] [Abstract][Full Text] [Related]
28. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
[TBL] [Abstract][Full Text] [Related]
29. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
30. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225
[TBL] [Abstract][Full Text] [Related]
31. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
32. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
[TBL] [Abstract][Full Text] [Related]
33. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Canaani J; Labopin M; Huang XJ; Arcese W; Ciceri F; Blaise D; Irrera G; Corral LL; Bruno B; Santarone S; Van Lint MT; Vitek A; Esteve J; Mohty M; Nagler A
Am J Hematol; 2018 Jun; 93(6):736-744. PubMed ID: 29498106
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples.
Shih LY; Huang CF; Wu JH; Wang PN; Lin TL; Dunn P; Chou MC; Kuo MC; Tang CC
Clin Cancer Res; 2004 Feb; 10(4):1326-32. PubMed ID: 14977832
[TBL] [Abstract][Full Text] [Related]
35. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
36. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
Hosono N; Yokoyama H; Aotsuka N; Ando K; Iida H; Ishikawa T; Usuki K; Onozawa M; Kizaki M; Kubo K; Kuroda J; Kobayashi Y; Shimizu T; Chiba S; Nara M; Hata T; Hidaka M; Fujiwara SI; Maeda Y; Morita Y; Kusano M; Lu Q; Miyawaki S; Berrak E; Hasabou N; Naoe T
Int J Clin Oncol; 2021 Nov; 26(11):2131-2141. PubMed ID: 34363558
[TBL] [Abstract][Full Text] [Related]
37. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.
Dalal BI; Mansoor S; Manna M; Pi S; Sauro GD; Hogge DE
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):274-9. PubMed ID: 22481022
[TBL] [Abstract][Full Text] [Related]
38. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML.
Li W; Zhang L; Huang L; Mi Y; Wang J
Leuk Res; 2012 Feb; 36(2):186-91. PubMed ID: 21907407
[TBL] [Abstract][Full Text] [Related]
40. Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Boluda B; Martínez-Cuadrón D; Algarra L; Cano I; Sayas MJ; Acuña-Cruz E; Blanco A; Marco-Ayala J; DeLapuerta R; Díaz-González Á; Tormo M; Rodríguez-Veiga R; García R; Piñana JL; López-Pavía M; Barragán E; Amigo ML; Sargas C; López A; Solana-Altabella A; Gil C; Megías-Vericat JE; Sanz MA; Montesinos P
Leuk Lymphoma; 2021 Nov; 62(11):2727-2736. PubMed ID: 34121593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
